issuer: Oxygen Biotherapeutics Inc. One Copley Parkway, Suite 490 US-27560 Morrisville, NC phone: +1 (919) 855 21 12 FAX: +1 (919) 806 44 17 mail: e.corliss@oxybiomed.com WWW: www.oxybiomed.com sector: Biotechnology ISIN: US69207P2092 indexes: SSIRT stockmarkets: Nasdaq: New York, Main Standard: SIX Swiss Exchange ...
issuer: Oxygen Biotherapeutics Inc. One Copley Parkway, Suite 490 US-27560 Morrisville, NC phone: +1 (919) 855 21 12 FAX: +1 (919) 806 44 17 mail: e.corliss@oxybiomed.com WWW: www.oxybiomed.com sector: Biotechnology ISIN: US69207P2092 indexes: SSIRT stockmarkets: Nasdaq: New York, Main Standard: SIX Swiss Exchange ...
issuer: Oxygen Biotherapeutics Inc. One Copley Parkway, Suite 490 US-27560 Morrisville, NC phone: +1 (919) 855 21 12 FAX: +1 (919) 806 44 17 mail: e.corliss@oxybiomed.com WWW: www.oxybiomed.com sector: Biotechnology ISIN: US69207P2092 indexes: SSIRT stockmarkets: Nasdaq: New York, Main Standard: SIX Swiss Exchange ...
issuer: Oxygen Biotherapeutics Inc. One Copley Parkway, Suite 490 US-27560 Morrisville, NC phone: +1 (919) 855 21 12 FAX: +1 (919) 806 44 17 mail: e.corliss@oxybiomed.com WWW: www.oxybiomed.com sector: Biotechnology ISIN: US69207P2092 indexes: SSIRT stockmarkets: Nasdaq: New York, Main Standard: SIX Swiss Exchange language: English ...
issuer: Oxygen Biotherapeutics Inc. One Copley Parkway, Suite 490 US-27560 Morrisville, NC phone: +1 (919) 855 21 12 FAX: +1 (919) 806 44 17 mail: e.corliss@oxybiomed.com WWW: www.oxybiomed.com sector: Biotechnology ISIN: US69207P2092 indexes: SSIRT stockmarkets: Nasdaq: New York, Main Standard: SIX Swiss Exchange ...
issuer: Oxygen Biotherapeutics Inc. 2530 Meridian Pkwy US-27713 Durham, NC phone: +1(919)7607606 FAX: +1(419)7108764 mail: c.stern@oxybiomed.com WWW: www.oxybiomed.com sector: Biotechnology ISIN: US69207P2092 indexes: SSIRT stockmarkets: Nasdaq: New York, Main Standard: SIX Swiss Exchange language: English ...
issuer: Oxygen Biotherapeutics Inc. 2530 Meridian Pkwy US-27713 Durham, NC phone: +1(919)7607606 FAX: +1(419)7108764 mail: c.stern@oxybiomed.com WWW: www.oxybiomed.com sector: Biotechnology ISIN: US69207P2092 indexes: SSIRT stockmarkets: Nasdaq: New York, Main Standard: SIX Swiss Exchange language: English ...
issuer: Oxygen Biotherapeutics Inc. 2530 Meridian Pkwy US-27713 Durham, NC phone: +1(919)7607606 FAX: +1(419)7108764 mail: c.stern@oxybiomed.com WWW: www.oxybiomed.com sector: Biotechnology ISIN: US69207P2092 indexes: SSIRT stockmarkets: Nasdaq: New York, Main Standard: SIX Swiss Exchange language: English ...
issuer: Oxygen Biotherapeutics Inc. 2530 Meridian Pkwy US-27713 Durham, NC phone: +1(919)7607606 FAX: +1(419)7108764 mail: c.stern@oxybiomed.com WWW: www.oxybiomed.com sector: Biotechnology ISIN: US69207P2092 indexes: SSIRT stockmarkets: Nasdaq: New York, Main Standard: SIX Swiss Exchange language: English ...
Contact: Ellen Corliss Vice President, Corporate Communications & Investor Relations Oxygen Biotherapeutics, Inc 2530 Meridian Pkwy, 3rd floor Durham, NC 27713 Direct Telephone: +1 919 855 2112 Direct Fax: +1 919 806 4417 Email: e.corliss@oxybiomed.com Branche: Biotechnology ISIN: US69207P2092 WKN: 10728277 Index: SSIRT Börsen: New York / Nasdaq SIX Swiss Exchange / ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Contracts 28.01.2011 DURHAM, NC, January 28, 2011 - Oxygen Biotherapeutics, Inc. (NASDAQ & SIX Swiss Exchange: OXBT) today announced it has signed ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Contracts 13.01.2011 DURHAM, NC, January 13, 2011 - Oxygen Biotherapeutics, Inc. (NASDAQ & SIX Swiss Exchange: OXBT) today announced it has entered ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. quarterly report 10.12.2010 DURHAM, NC, December 9, 2010 Oxygen Biotherapeutics, Inc. (NASDAQ and SIX Swiss Exchange: OXBT), a development stage biomedical company focused on developing oxygen-rich ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Biotechnology 13.10.2010 DURHAM, NC, September 13, 2010 - Oxygen Biotherapeutics, Inc. (NASDAQ & SIX Swiss Exchange: OXBT) Dr. Antoine Carlisle ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Research & Development/Biotechnology 23.09.2010 DURHAM, NC, September 23, 2010 - Oxygen Biotherapeutics, Inc. (NASDAQ & SIX Swiss Exchange: OXBT) ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Research & Development 20.09.2010 DURHAM, NC, September 20, 2010 - Oxygen Biotherapeutics, Inc. (NASDAQ & SIX Swiss Exchange: OXBT) today announced it has amended an existing Cooperative Research and Development Agreement (CRADA) with the U.S. Naval ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. quarterly report/Biotechnology 10.09.2010 DURHAM, NC, September 9, 2010 Oxygen Biotherapeutics, Inc. (NASDAQ and SIX Swiss Exchange: OXBT), a development stage biomedical company focused on ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Study/Biotechnology 08.09.2010 DURHAM, NC, September 7, 2010 Oxygen Biotherapeutics, Inc. (NASDAQ and SIX Swiss Exchange: OXBT), a development stage biomedical company focused on developing ...
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. New Products/Biotechnology Durham, NC (euro adhoc) - DURHAM, NC, July 28, 2010 Oxygen Biotherapeutics, Inc. (NASDAQ & SIX Swiss Exchange: OXBT) today introduced its new, innovative ...
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Company Information/Research & Development/Biotechnology Durham, NC (euro adhoc) - Oxycyte® PFCE Decreases Mortality From Decompression Sickness in Preclinical Study DURHAM, NC, June ...
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Company Information/Research & Development/Biotechnology Durham, NC (euro adhoc) - Press Release Oxygen Biotherapeutics Inc.: Study Shows Marked Neuroprotective Effects of Oxycyte® ...
Oxygen Biotherapeutics Builds New Relationships for Dermacyte Products and Traumatic Brain Injury Clinical Trials Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Company Information/Contracts/Marketing/Biotechnology Subtitle: Oxygen Biotherapeutics Builds New Relationships for Dermacyte Products and Traumatic Brain Injury Clinical ...
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Company Information/Marketing/New Products/Biotechnology Durham, NC (euro adhoc) - Press Release Oxygen Biotherapeutics Inc.: Oxygen Biotherapeutics Now Marketing New Formulation of ...